Inflammation and cancer: how friendly is the relationship for cancer patients?

Current Opinion in Pharmacology

Volumn 9, Issue 4, 2009, Pages 351-369

  Aggarwal, Bharat B ^a   Gehlot, Prashasnika ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BORTEZOMIB; C REACTIVE PROTEIN; CHEMOKINE; CURCUMIN; CYCLIN D1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; ETANERCEPT; GELATINASE B; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6; LIPOXYGENASE; MYC PROTEIN; PREDNISOLONE; PROTEASOME INHIBITOR; STAT3 PROTEIN; STEROID; THALIDOMIDE; TRANSCRIPTION FACTOR TWIST; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN;

BRAIN CANCER; BREAST CANCER; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; LEUKEMIA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; TUMOR CELL; UROGENITAL TRACT CANCER;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIFE STYLE; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 68849108869     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2009.06.020     Document Type: Review

References (270)

1. Heidland A., Klassen A., Rutkowski P., and Bahner U. The contribution of Rudolf Virchow to the concept of inflammation: what is still of importance?. J Nephrol 19 Suppl 10 (2006) S102-S109
2. Vilimas T., Mascarenhas J., Palomero T., Mandal M., Buonamici S., Meng F., Thompson B., Spaulding C., Macaroun S., Alegre M.L., et al. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 13 (2007) 70-77. An important evidence for the role of NF-κB in leukemia.
3. Lee K.J., Kim H.A., Kim P.H., Lee H.S., Ma K.R., Park J.H., Kim D.J., and Hahn J.H. Ox-LDL suppresses PMA-induced MMP-9 expression and activity through CD36-mediated activation of PPAR-g. Exp Mol Med 36 (2004) 534-544
4. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G.Y., Vallabhapurapu S., Scheller J., Rose-John S., Cheroutre H., Eckmann L., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15 (2009) 103-113
5. Du Q., Zhang X., Cardinal J., Cao Z., Guo Z., Shao L., and Geller D.A. Wnt/beta-catenin ignaling regulates cytokine-induced human inducible nitric oxide synthase expression by nhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res. 69 (2009) 3764-3771
6. Monteghirfo S., Tosetti F., Ambrosini C., Stigliani S., Pozzi S., Frassoni F., Fassina G., Soverini S., Albini A., and Ferrari N. Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation. Mol Cancer Ther 7 (2008) 2692-2702
7. Fujioka S., Niu J., Schmidt C., Sclabas G.M., Peng B., Uwagawa T., Li Z., Evans D.B., Abbruzzese J.L., and Chiao P.J. NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity. Mol Cell Biol 24 (2004) 7806-7819
8. Aggarwal B.B., Vijayalekshmi R.V., and Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15 (2009) 425-430
9. Guzman M.L., Neering S.J., Upchurch D., Grimes B., Howard D.S., Rizzieri D.A., Luger S.M., and Jordan C.T. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98 (2001) 2301-2307
10. Guzman M.L., Rossi R.M., Neelakantan S., Li X., Corbett C.A., Hassane D.C., Becker M.W., Bennett J.M., Sullivan E., Lachowicz J.L., et al. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood 110 (2007) 4427-4435
11. Braun T., Carvalho G., Coquelle A., Vozenin M.C., Lepelley P., Hirsch F., Kiladjian J.J., Ribrag V., Fenaux P., and Kroemer G. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107 (2006) 1156-1165
12. Birnie R., Bryce S.D., Roome C., Dussupt V., Droop A., Lang S.H., Berry P.A., Hyde C.F., Lewis J.L., Stower M.J., et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 9 (2008) R83
13. Widera D., Kaus A., Kaltschmidt C., and Kaltschmidt B. Neural stem cells, inflammation and NF-kappaB: basic principle of maintenance and repair or origin of brain tumours?. J Cell Mol Med 12 (2008) 459-470
14. Zhou J., and Zhang Y. Cancer stem cells: models, mechanisms and implications for improved treatment. Cell Cycle 7 (2008) 1360-1370
15. Ismail H.A., Lessard L., Mes-Masson A.M., and Saad F. Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 58 (2004) 308-313. Provides the first evidence for the role of NF-kB in prostate cancer.
16. Lessard L., Begin L.R., Gleave M.E., Mes-Masson A.M., and Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 93 (2005) 1019-1023
17. Zhang P.L., Pellitteri P.K., Law A., Gilroy P.A., Wood G.C., Kennedy T.L., Blasick T.M., Lun M., Schuerch III C., and Brown R.E. Overexpression of phosphorylated nuclear factor-kappa B in tonsillar squamous cell carcinoma and high-grade dysplasia is associated with poor prognosis. Mod Pathol 18 (2005) 924-932
18. Mishra A., Bharti A.C., Varghese P., Saluja D., and Das B.C. Differential expression and activation of NF-kappaB family proteins during oral carcinogenesis: role of high risk human papillomavirus infection. Int J Cancer 119 (2006) 2840-2850
19. Izzo J.G., Malhotra U., Wu T.T., Luthra R., Correa A.M., Swisher S.G., Hofstetter W., Chao K.S., Hung M.C., and Ajani J.A. Clinical biology of esophageal adenocarcinoma after surgery is influenced by nuclear factor-kappaB expression. Cancer Epidemiol Biomarkers Prev 16 (2007) 1200-1205
20. Izzo J.G., Malhotra U., Wu T.T., Ensor J., Luthra R., Lee J.H., Swisher S.G., Liao Z., Chao K.S., Hittelman W.N., et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 24 (2006) 748-754
21. Tang X., Liu D., Shishodia S., Ozburn N., Behrens C., Lee J.J., Hong W.K., Aggarwal B.B., and Wistuba I.I. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107 (2006) 2637-2646
22. Niesporek S., Weichert W., Sinn B., Röske A., Noske A., Buckendahl A.C., Wirtz R., Sehouli J., Koensgen D., Dietel M., et al. NF-kappaB subunit p65/RelA expression in ovarian carcinoma: prognostic impact and link to COX-2 overexpression. Verh Dtsch Ges Pathol 91 (2007) 243-249
23. Lerebours F., Vacher S., Andrieu C., Espie M., Marty M., Lidereau R., and Bieche I. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8 (2008) 41
24. Zhou Y., Eppenberger-Castori S., Marx C., Yau C., Scott G.K., Eppenberger U., and Benz C.C. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37 (2005) 1130-1144
25. Garg A.K., Hortobagyi G.N., Aggarwal B.B., Sahin A.A., and Buchholz T.A. Nuclear factor-kappa B as a predictor of treatment response in breast cancer. Curr Opin Oncol 15 (2003) 405-411. Shows NF-κB as a predictor of response in breast cancer.
26. Boehm J.S., Zhao J.J., Yao J., Kim S.Y., Firestein R., Dunn I.F., Sjostrom S.K., Garraway L.A., Weremowicz S., Richardson A.L., et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129 (2007) 1065-1079
27. Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.J., Van Wier S., Tiedemann R., Shi C.X., Sebag M., et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12 (2007) 131-144
28. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12 (2007) 115-130
29. Bharti A.C., Shishodia S., Reuben J.M., Weber D., Alexanian R., Raj-Vadhan S., Estrov Z., Talpaz M., and Aggarwal B.B. Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 103 (2004) 3175-3184
30. Frank D.A., Mahajan S., and Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 100 (1997) 3140-3148
31. Kanda N., Seno H., Konda Y., Marusawa H., Kanai M., Nakajima T., Kawashima T., Nanakin A., Sawabu T., Uenoyama Y., et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23 (2004) 4921-4929
32. Haura E.B., Zheng Z., Song L., Cantor A., and Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11 (2005) 8288-8294
33. Liu B., Ren Z., Shi Y., Guan C., Pan Z., and Zong Z. Activation of signal transducers and activators of transcription 3 and overexpression of its target gene CyclinD1 in laryngeal carcinomas. Laryngoscope 118 (2008) 1976-1980
34. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., Baumann H., and Wetzler M. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99 (2002) 252-257
35. Khor L.Y., Bae K., Pollack A., Hammond M.E., Grignon D.J., Venkatesan V.M., Rosenthal S.A., Ritter M.A., Sandler H.M., Hanks G.E., et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8 (2007) 912-920
36. Khor L.Y., Bae K., Pollack A., Hammond M.E., Grignon D.J., Venkatesan V.M., Rosenthal S.A., Ritter M.A., Sandler H.M., Hanks G.E., et al. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 119 (2006) 1082-1087
37. Khuri F.R., Wu H., Lee J.J., Kemp B.L., Lotan R., Lippman S.M., Feng L., Hong W.K., and Xu X.C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res 7 (2001) 861-867
38. Pannone G., Bufo P., Caiaffa M.F., Serpico R., Lanza A., Lo Muzio L., Rubini C., Staibano S., Petruzzi M., De Benedictis M., et al. Cyclooxygenase-2 expression in oral squamous cell carcinoma. Int J Immunopathol Pharmacol 17 (2004) 273-282
39. Yang G.Z., Li L., Ding H.Y., and Zhou J.S. Cyclooxygenase-2 is over-expressed in Chinese esophageal squamous cell carcinoma, and correlated with NF-kappaB: an immunohistochemical study. Exp Mol Pathol 79 (2005) 214-218
40. Ohsawa M., Fukushima H., Ikura Y., Inoue T., Shirai N., Sugama Y., Suekane T., Kitabayashi C., Nakamae H., Hino M., et al. Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis. Leuk Lymphoma 47 (2006) 1863-1871
41. Trojan A., Tinguely M., Vallet S., Seifert B., Jenni B., Zippelius A., Witzens-Harig M., Mechtersheimer G., Ho A., Goldschmidt H., et al. Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma. Swiss Med Wkly 136 (2006) 400-403
42. Zhang X.H., Huang D.P., Guo G.L., Chen G.R., Zhang H.X., Wan L., and Chen S.Y. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 8 (2008) 4
43. Cetin M., Buyukberber S., Demir M., Sari I., Sari I., Deniz K., Eser B., Altuntas F., Camci C., Oztürk A., et al. Overexpression of cyclooxygenase-2 in multiple myeloma: association with reduced survival. Am J Hematol 80 (2005) 169-173
44. Kim Y.B., Kim G.E., Cho N.H., Pyo H.R., Shim S.J., Chang S.K., Park H.C., Suh C.O., Park T.K., and Kim B.S. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 95 (2002) 531-539
45. Shim S.J., Yang W.I., Shin E., Koom W.S., Kim Y.B., Cho J.H., Suh C.O., Kim J.H., and Kim G.E. Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys 67 (2007) 31-38
46. Balkwill F., Osborne R., Burke F., Naylor S., Talbot D., Durbin H., Tavernier J., and Fiers W. Evidence for tumour necrosis factor/cachectin production in cancer. Lancet 2 (1987) 1229-1232. An earliest reported indication about the role of inflammation in cancer.
47. Punnonen J., Heinonen P.K., Kuoppala T., Jansen C.T., and Punnonen R. Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours. J Cancer Res Clin Oncol 117 (1991) 587-592
48. Ferrajoli A., Keating M.J., Manshouri T., Giles F.J., Dey A., Estrov Z., Koller C.A., Kurzrock R., Thomas D.A., Faderl S., et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 100 (2002) 1215-1219
49. Kai H., Kitadai Y., Kodama M., Cho S., Kuroda T., Ito M., Tanaka S., Ohmoto Y., and Chayama K. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res 25 (2005) 709-713
50. Miki C., Konishi N., Ojima E., Hatada T., Inoue Y., and Kusunoki M. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci 49 (2004) 970-976
51. Deans D.A., Wigmore S.J., Gilmour H., Paterson-Brown S., Ross J.A., and Fearon K.C. Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 95 (2006) 1568-1575
52. Abramov Y., Anteby S.O., Fasouliotis S.J., and Barak V. The role of inflammatory cytokines in Meigs' syndrome. Obstet Gynecol 99 (2002) 917-919
53. Klein B., and Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am 6 (1992) 273-284
54. Sharma R., Zucknick M., London R., Kacevska M., Liddle C., and Clarke S.J. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer 7 (2008) 331-337
55. Offner F.A., Obrist P., Stadlmann S., Feichtinger H., Klingler P., Herold M., Zwierzina H., Hittmair A., Mikuz G., Abendstein B., et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 7 (1995) 542-547
56. Rubie C., Frick V.O., Pfeil S., Wagner M., Kollmar O., Kopp B., Graber S., Rau B.M., and Schilling M.K. Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol 13 (2007) 4996-5002
57. Terada H., Urano T., and Konno H. Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res 37 (2005) 166-172
58. Haraguchi M., Komuta K., Akashi A., Matsuzaki S., Furui J., and Kanematsu T. Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis. Oncol Rep 9 (2002) 159-165
59. Kubo F., Ueno S., Hiwatashi K., Sakoda M., Kawaida K., Nuruki K., and Aikou T. Interleukin 8 in human hepatocellular carcinoma correlates with cancer cell invasion of vessels but not with tumor angiogenesis. Ann Surg Oncol 12 (2005) 800-807
60. Murphy C., McGurk M., Pettigrew J., Santinelli A., Mazzucchelli R., Johnston P.G., Montironi R., and Waugh D.J. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11 (2005) 4117-4127
61. Horikawa T., Kaizaki Y., Kato H., Furukawa M., and Yoshizaki T. Expression of interleukin-8 receptor A predicts poor outcome in patients with nasopharyngeal carcinoma. Laryngoscope 115 (2005) 62-67
62. Kido S., Kitadai Y., Hattori N., Haruma K., Kido T., Ohta M., Tanaka S., Yoshihara M., Sumii K., Ohmoto Y., et al. Interleukin 8 and vascular endothelial growth factor -- prognostic factors in human gastric carcinomas?. Eur J Cancer 37 (2001) 1482-1487
63. Yuan A., Yang P.C., Yu C.J., Chen W.J., Lin F.Y., Kuo S.H., and Luh K.T. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med 162 (2000) 1957-1963
64. Kassim S.K., El-Salahy E.M., Fayed S.T., Helal S.A., Helal T., Azzam E.-D., and Khalifa A. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem 37 (2004) 363-369
65. Nurnberg W., Tobias D., Otto F., Henz B.M., and Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 189 (1999) 546-551
66. Woo S.U., Bae J.W., Kim C.H., Lee J.B., and Koo B.W. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol 15 (2008) 281-285
67. Darash-Yahana M., Pikarsky E., Abramovitch R., Zeira E., Pal B., Karplus R., Beider K., Avniel S., Kasem S., Galun E., et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18 (2004) 1240-1242
68. Kaifi J.T., Yekebas E.F., Schurr P., Obonyo D., Wachowiak R., Busch P., Heinecke A., Pantel K., and Izbicki J.R. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst 97 (2005) 1840-1847
69. Yoshitake N., Fukui H., Yamagishi H., Sekikawa A., Fujii S., Tomita S., Ichikawa K., Imura J., Hiraishi H., and Fujimori T. Expression of SDF-1 alpha and nuclear CXCR4 predicts lymph node metastasis in colorectal cancer. Br J Cancer 98 (2008) 1682-1689
70. Su L., Zhang J., Xu H., Wang Y., Chu Y., Liu R., and Xiong S. Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 11 (2005) 8273-8280
71. Wagner P.L., Moo T.A., Arora N., Liu Y.F., Zarnegar R., Scognamiglio T., and Fahey III T.J. The chemokine receptors CXCR4 and CCR7 are associated with tumor size and pathologic indicators of tumor aggressiveness in papillary thyroid carcinoma. Ann Surg Oncol 15 (2008) 2833-2841
72. Woerner B.M., Warrington N.M., Kung A.L., Perry A., Rubin J.B., and Widespread. CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res 65 (2005) 11392-11399
73. Russell H.V., Hicks J., Okcu M.F., and Nuchtern J.G. CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg 39 (2004) 1506-1511
74. Kucia M., Reca R., Miekus K., Wanzeck J., Wojakowski W., Janowska-Wieczorek A., Ratajczak J., and Ratajczak M.Z. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 23 (2005) 879-894
75. Gelmini S., Mangoni M., Castiglione F., Beltrami C., Pieralli A., Andersson K.L., Fambrini M., Taddei G.L., Serio M., and Orlando C. The CXCR4/CXCL12 axis in endometrial cancer. Clin Exp Metastasis 26 (2009) 261-268
76. Faronato M., Muzzonigro G., Milanese G., Menna C., Bonfigli A.R., Catalano A., and Procopio A. Increased expression of 5-lipoxygenase is common in clear cell renal cell carcinoma. Histol Histopathol 22 (2007) 1109-1118
77. Jiang W.G., Douglas-Jones A.G., and Mansel R.E. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer. Prostaglandins Leukot Essent Fatty Acids 74 (2006) 125-134
78. Hennig R., Grippo P., Ding X.Z., Rao S.M., Buchler M.W., Friess H., Talamonti M.S., Bell R.H., and Adrian T.E. 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions. Cancer Res 65 (2005) 6011-6016
79. Jiang W.G., Douglas-Jones A., and Mansel R.E. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 69 (2003) 275-281
80. Gao X., Grignon D.J., Chbihi T., Zacharek A., Chen Y.Q., Sakr W., Porter A.T., Crissman J.D., Pontes J.E., Powell I.J., et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 46 (1995) 227-237
81. Maekawa S., Iwasaki A., Shirakusa T., Enatsu S., Kawakami T., Kuroki M., and Kuroki M. Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. Anticancer Res 27 (2007) 3735-3741
82. Li J., Li B.L., Zhang H.Q., Xu S.F., Liu Z.D., Yue W.T., and Han Y. Relationship between vascular endothelial growth factor C expression level and lymph node metastasis in non small cell lung cancer. Zhonghua Yi Xue Za Zhi 88 (2008) 2982-2985
83. Jia J.B., Zhuang P.Y., Sun H.C., Zhang J.B., Zhang W., Zhu X.D., Xiong Y.Q., Xu H.X., and Tang Z.Y. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol 135 (2009) 847-854
84. Kim J.G., Chae Y.S., Sohn S.K., Cho Y.Y., Moon J.H., Park J.Y., Jeon S.W., Lee I.T., Choi G.S., and Jun S.H. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14 (2008) 62-66
85. Duncan T.J., Al-Attar A., Rolland P., Scott I.V., Deen S., Liu D.T., Spendlove I., and Durrant L.G. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?. Clin Cancer Res 14 (2008) 3030-3035
86. Tian X., Cong M., Zhou W., Zhu J., and Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res 36 (2008) 699-703
87. Tang H., Wang J., Bai F., Zhai H., Gao J., Hong L., Xie H., Zhang F., Lan M., Yao W., et al. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. Cancer Invest 26 (2008) 60-67
88. Li Y.H., Hu C.F., Shao Q., Huang M.Y., Hou J.H., Xie D., Zeng Y.X., and Shao J.Y. Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 6 (2008) 1
89. Zhang B., Zhao W.H., Zhou W.Y., Yu W.S., Yu J.M., and Li S. Expression of vascular endothelial growth factors-C and -D correlate with evidence of lymphangiogenesis and angiogenesis in pancreatic adenocarcinoma. Cancer Detect Prev 31 (2007) 436-442
90. Boone B., Blokx W., De Bacquer D., Lambert J., Ruiter D., and Brochez L. The role of VEGF-C staining in predicting regional metastasis in melanoma. Virchows Arch 453 (2008) 257-265
91. Dikov M.M., Oyama T., Cheng P., Takahashi T., Takahashi K., Sepetavec T., Edwards B., Adachi Y., Nadaf S., Daniel T., et al. Vascular endothelial growth factor effects on nuclear factor-kappaB activation in hematopoietic progenitor cells. Cancer Res 61 (2001) 2015-2021
92. Rajnakova A., Moochhala S., Goh P.M., and Ngoi S. Expression of nitric oxide synthase, cyclooxygenase, and p53 in different stages of human gastric cancer. Cancer Lett 172 (2001) 177-185
93. Broholm H., Rubin I., Kruse A., Braendstrup O., Schmidt K., Skriver E.B., and Lauritzen M. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin Neuropathol 22 (2003) 273-281
94. Wilson K.T., Fu S., Ramanujam K.S., and Meltzer S.J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58 (1998) 2929-2934
95. Ekmekcioglu S., Ellerhorst J.A., Prieto V.G., Johnson M.M., Broemeling L.D., and Grimm E.A. Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 119 (2006) 861-866
96. Hayashi H., Kuwahara M., Fujisaki N., Furihata M., Ohtsuki Y., and Kagawa S. Immunohistochemical findings of nitric oxide synthase expression in urothelial transitional cell carcinoma including dysplasia. Oncol Rep 8 (2001) 1275-1279
97. O'Hanlon D.M., Lynch J., Cormican M., and Given H.F. The acute phase response in breast carcinoma. Anticancer Res 22 (2002) 1289-1293
98. Cahlin C., Lonnroth C., Arvidsson A., Nordgren S., and Lundholm K. Growth associated proteins in tumor cells and stroma related to disease progression of colon cancer accounting for tumor tissue PGE2 content. Int J Oncol 32 (2008) 909-918
99. Jabs W.J., Busse M., Kruger S., Jocham D., Steinhoff J., and Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 68 (2005) 2103-2110
100. Zakrzewska I., and Poznanski J. Changes of serum il-6 and CRP after chemotherapy in patients with ovarian carcinoma. Pol Merkur Lekarski 11 (2001) 210-213
101. Yudoh K., Matsui H., Kamanori M., Ohmori K., Yasuda T., Tsuji H., and Tatezaki S. Prognostic value of the doubling time of serum C-reactive protein and alkaline phosphatase levels in primary bone and soft tissue tumors. Jpn J Cancer Res 87 (1996) 1288-1295
102. Kamble R., Wilson C.S., Fassas A., Desikan R., Siegel D.S., Tricot G., Anderson P., Sawyer J., Anaissie E., Barlogie B., et al. Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma 46 (2005) 1137-1142
103. Reichle A., Bross K., Vogt T., Bataille F., Wild P., Berand A., Krause S.W., and Andreesen R. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 101 (2004) 2247-2256
104. Bien E., and Balcerska A. Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer. Med Wieku Rozwoj 8 (2004) 1081-1089
105. Chen X.L., Wang L.C., Zhang W.G., Chen X.Y., and Sun Z.M. Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer. Nan Fang Yi Ke Da Xue Xue Bao 28 (2008) 1254-1258
106. Guo C.B., Wang S., Deng C., Zhang D.L., Wang F.L., and Jin X.Q. Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther 11 (2007) 183-192
107. Hu Z.L., Wen J.F., Shen M., and Liu Y. Expressions of TGIF, MMP9 and VEGF proteins and their clinicopathological relationship in gastric cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31 (2006) 70-74
108. Gu Z.D., Li J.Y., Li M., Gu J., Shi X.T., Ke Y., and Chen K.N. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am J Gastroenterol 100 (2005) 1835-1843
109. Sakata K., Satoh M., Someya M., Asanuma H., Nagakura H., Oouchi A., Nakata K., Kogawa K., Koito K., Hareyama M., et al. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Cancer 100 (2004) 356-365
110. Kallakury B.V., Karikehalli S., Haholu A., Sheehan C.E., Azumi N., and Ross J.S. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7 (2001) 3113-3119
111. Benassi M.S., Gamberi G., Magagnoli G., Molendini L., Ragazzini P., Merli M., Chiesa F., Balladelli A., Manfrini M., Bertoni F., et al. Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol 12 (2001) 75-80
112. Hoechtlen-Vollmar W., Menzel G., Bartl R., Lamerz R., Wick M., and Seidel D. Amplification of cyclin D1 gene in multiple myeloma: clinical and prognostic relevance. Br J Haematol 109 (2000) 30-38
113. Munzert G., Kirchner D., Ottmann O., Bergmann L., and Schmid R.M. Constitutive NF-kappab/Rel activation in Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). Leuk Lymphoma 45 (2004) 1181-1184
114. Zaninoni A., Imperiali F.G., Pasquini C., Zanella A., and Barcellini W. Cytokine modulation of nuclear factor-kappaB activity in B-chronic lymphocytic leukemia. Exp Hematol 31 (2003) 185-190
115. Hewamana S., Lin T.T., Rowntree C., Karunanithi K., Pratt G., Hills R., Fegan C., Brennan P., and Pepper C. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res 14 (2008) 8102-8111
116. Hewamana S., Lin T.T., Rowntree C., Karunanithi K., Pratt G., Hills R., Fegan C., Brennan P., and Pepper C. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 27 (2009) 763-769
117. Martínez-Delgado B., Cuadros M., Honrado E., Ruiz de la Parte A., Roncador G., Alves J., Castrillo J.M., Rivas C., and Benítez J. Differential expression of NF-kappaB pathway genes among peripheral T-cell lymphomas. Leukemia 19 (2005) 2254-2263
118. Kuo S.H., Chen L.T., Yeh K.H., Wu M.S., Hsu H.C., Yeh P.Y., Mao T.L., Chen C.L., Doong S.L., Lin J.T., et al. Nuclear expression of BCL10 or nuclear factor kappa B predicts Helicobacter pylori-independent status of early-stage, high-grade gastric mucosa-associated lymphoid tissue lymphomas. J Clin Oncol 22 (2004) 3491-3497
119. Yeh K.H., Kuo S.H., Chen L.T., Mao T.L., Doong S.L., Wu M.S., Hsu H.C., Tzeng Y.S., Chen C.L., Lin J.T., et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 106 (2005) 1037-1041
120. Valnet-Rabier M.B., Challier B., Thiebault S., Angonin R., Margueritte G., Mougin C., Kantelip B., Deconinck E., Cahn J.Y., and Fest T. c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. Br J Haematol 128 (2005) 767-773
121. Ruiz-Ballesteros E., Mollejo M., Rodriguez A., Camacho F.I., Algara P., Martinez N., Pollán M., Sanchez-Aguilera A., Menarguez J., Campo E., et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 106 (2005) 1831-1838
122. Bargou R.C., Leng C., Krappmann D., Emmerich F., Mapara M.Y., Bommert K., Royer H.D., Scheidereit C., and Dörken B. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 87 (1996) 4340-4347
123. Emmerich F., Meiser M., Hummel M., Demel G., Foss H.D., Jundt F., Mathas S., Krappmann D., Scheidereit C., Stein H., et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94 (1999) 3129-3134
124. Houldsworth J., Petlakh M., Olshen A.B., and Chaganti R.S. Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response. Leuk Lymphoma 49 (2008) 2170-2180
125. Santhi W.S., Sebastian P., Varghese B.T., Prakash O., and Pillai M.R. NF-kappaB and COX-2 during oral tumorigenesis and in assessment of minimal residual disease in surgical margins. Exp Mol Pathol 81 (2006) 123-130
126. Logan R.M., Gibson R.J., Sonis S.T., and Keefe D.M. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43 (2007) 395-401
127. Rhodus N.L., Cheng B., Myers S., Bowles W., Ho V., and Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 114 (2005) 278-283
128. Rhodus N.L., Ho V., Miller C.S., Myers S., and Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 29 (2005) 42-45
129. Izzo J.G., Correa A.M., Wu T.T., Malhotra U., Chao C.K., Luthra R., Ensor J., Dekovich A., Liao Z., Hittelman W.N., et al. Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 5 (2006) 2844-2850
130. Gan H., Ouyang Q., Chen Y., and Xia Q. Activation of nuclear factor-kappaB and effects of anti-inflammatory treatment thereon in intestinal mucosa of patients with ulcerative colitis. Zhonghua Yi Xue Za Zhi 82 (2002) 384-388
131. Tai D.I., Tsai S.L., Chang Y.H., Huang S.N., Chen T.C., Chang K.S., and Liaw Y.F. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 89 (2000) 2274-2281
132. Weichert W., Boehm M., Gekeler V., Bahra M., Langrehr J., Neuhaus P., Denkert C., Imre G., Weller C., Hofmann H.P., et al. High expression of RelA/p65 is associated with activation of nuclear factor-kappaB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. Br J Cancer 97 (2007) 523-530
133. O'Neil B.H., Bůzková P., Farrah H., Kashatus D., Sanoff H., Goldberg R.M., Baldwin A.S., and Funkhouser W.K. Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology 72 (2007) 97-104
134. Asakawa M., Kono H., Amemiya H., Matsuda M., Suzuki T., Maki A., and Fujii H. Role of interleukin-18 and its receptor in hepatocellular carcinoma associated with hepatitis C virus infection. Int J Cancer 118 (2006) 564-570
135. Cascinu S., Scartozzi M., Carbonari G., Pierantoni C., Verdecchia L., Mariani C., Squadroni M., Antognoli S., Silva R.R., Giampieri R., et al. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin. Am J Clin Oncol 30 (2007) 526-530
136. Yamanaka N., Sasaki N., Tasaki A., Nakashima H., Kubo M., Morisaki T., Noshiro H., Yao T., Tsuneyoshi M., Tanaka M., et al. Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res 24 (2004) 1071-1075
137. Levidou G., Korkolopoulou P., Nikiteas N., Tzanakis N., Thymara I., Saetta A.A., Tsigris C., Rallis G., Vlasis K., and Patsouris E. Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaB a and prognostic significance. Virchows Arch 450 (2007) 519-527
138. Wu L., Pu Z., Feng J., Li G., Zheng Z., and Shen W. The ubiquitin-proteasome pathway and enhanced activity of NF-kappaB in gastric carcinoma. J Surg Oncol 97 (2008) 439-444
139. Voboril R., Voborilova J., Rychterova V., Jirasek T., and Dvorak J. Dissociated invasively growing cancer cells with NF-kappaB/p65 positivity after radiotherapy: a new marker for worse clinical outcome in rectal cancer? Preliminary data. Clin Exp Metastasis 25 (2008) 491-496
140. Levidou G., Saetta A.A., Korkolopoulou P., Papanastasiou P., Gioti K., Pavlopoulos P., Diamantopoulou K., Thomas-Tsagli E., Xiromeritis K., and Patsouris E. Clinical significance of nuclear factor (NF)-kappaB levels in urothelial carcinoma of the urinary bladder. Virchows Arch 452 (2008) 295-304
141. Riemann K., Becker L., Struwe H., Rubben H., Eisenhardt A., and Siffert W. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 45 (2007) 423-430
142. Fradet V., Lessard L., Begin L.R., Karakiewicz P., Masson A.M., and Saad F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10 (2004) 8460-8464
143. Domingo-Domenech J., Mellado B., Ferrer B., Truan D., Codony-Servat J., Sauleda S., Alcover J., Campo E., Gascon P., Rovira A., et al. Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 93 (2005) 1285-1294
144. Korkolopoulou P., Levidou G., Saetta A.A., El-Habr E., Eftichiadis C., Demenagas P., Thymara I., Xiromeritis K., Boviatsis E., Thomas-Tsagli E., et al. Expression of nuclear factor-kappaB in human astrocytomas: relation to pIkappaBa, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 39 (2008) 1143-1152
145. Yamamoto M., Fukushima T., Hayashi S., Ikeda K., Tsugu H., Kimura H., Soma G., and Tomonaga M. Correlation of the expression of nuclear factor-kappa B, tumor necrosis factor receptor type 1 (TNFR 1) and c-Myc with the clinical course in the treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res 20 (2000) 611-618
146. Conti A., Ageunnouz M., La Torre D., Cardali S., Angileri F.F., Buemi C., Tomasello C., Iacopino D.G., D'Avella D., Vita G., et al. Expression of the tumor necrosis factor receptor-associated factors 1 and 2 and regulation of the nuclear factor-kappaB antiapoptotic activity in human gliomas. J Neurosurg 103 (2005) 873-881
147. Hou M.F., Lin S.B., Yuan S.S., Tsai S.M., Wu S.H., Ou-Yang F., Hsieh J.S., Tsai K.B., Huang T.J., and Tsai L.Y. The clinical significance between activation of nuclear factor kappa B transcription factor and overexpression of HER-2/neu oncoprotein in Taiwanese patients with breast cancer. Clin Chim Acta 334 (2003) 137-144
148. Zhou Y., Eppenberger-Castori S., Eppenberger U., and Benz C.C. The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12 Suppl 1 (2005) S37-S46
149. Biswas D.K., Shi Q., Baily S., Strickland I., Ghosh S., Pardee A.B., and Iglehart J.D. NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 101 (2004) 10137-10142. An important evidence for the role of NF-κB in breast cancer.
150. Guo R.X., Qiao Y.H., Zhou Y., Li L.X., Shi H.R., and Chen K.S. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Int 58 (2008) 749-756
151. O'Riordan J.M., Abdel-latif M.M., Ravi N., McNamara D., Byrne P.J., McDonald G.S., Keeling P.W., Kelleher D., and Reynolds J.V. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Gastroenterol 100 (2005) 1257-1264
152. Meteoglu I., Erdogdu I.H., Meydan N., Erkus M., and Barutca S. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J Exp Clin Cancer Res 27 (2008) 53
153. Kourelis K., Sotiropoulou-Bonikou G., Vandoros G., Repanti M., Varakis I., and Goumas P. Coordinated upregulation of COX-2 and NF-kappaB is a steady feature of laryngeal carcinogenesis. ORL J Otorhinolaryngol Relat Spec 69 (2007) 181-189
154. Zhang D., Jin X., Wang F., Wang S., Deng C., Gao Z., and Guo C. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer. Ann Surg Oncol 14 (2007) 3581-3592
155. Bhojani M.S., Chen G., Ross B.D., Beer D.G., and Rehemtulla A. Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer. Cell Cycle 4 (2005) 1478-1481
156. Jin X., Wang Z., Qiu L., Zhang D., Guo Z., Gao Z., Deng C., Wang F., Wang S., and Guo C. Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Sci 99 (2008) 582-589
157. Zhang H.P., Xu Y.J., Zhang Z.X., Ni W., and Chen S.X. Expression of protein kinase C and nuclear factor kappa B in lung tissue of patients with chronic obstructive pulmonary disease. Zhonghua Nei Ke Za Zhi 43 (2004) 756-759
158. Gasparian A.V., Fedorova M.D., and Kisselev F.L. Regulation of matrix metalloproteinase-9 transcription in squamous cell carcinoma of uterine cervix: the role of human papillomavirus gene E2 expression and activation of transcription factor NF-kappaB. Biochemistry (Mosc) 72 (2007) 848-853
159. Kashani-Sabet M., Shaikh L., Miller III J.R., Nosrati M., Ferreira C.M., Debs R.J., and Sagebiel R.W. NF-kappa B in the vascular progression of melanoma. J Clin Oncol 22 (2004) 617-623
160. Gao K., Dai D.L., Martinka M., and Li G. Prognostic significance of nuclear factor-kappaB p105/p50 in human melanoma and its role in cell migration. Cancer Res 66 (2006) 8382-8388
161. Bao Z.H., Li G.L., and Yu J.H. Expression of cyclooxygenase-2 in bone marrow cells of chronic leukemia and its significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 15 (2007) 923-926
162. Li H.L., Sun B.Z., and Ma F.C. Expression of COX-2, iNOS, p53 and Ki-67 in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol 10 (2004) 1862-1866
163. Chang B.W., Kim D.H., Kowalski D.P., Burleson J.A., Son Y.H., Wilson L.D., and Haffty B.G. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res 10 (2004) 1678-1684
164. Ling F.C., Baldus S.E., Khochfar J., Xi H., Neiss S., Brabender J., Metzger R., Drebber U., Dienes H.P., Bollschweiler E., et al. Association of COX-2 expression with corresponding active and chronic inflammatory reactions in Barrett's metaplasia and progression to cancer. Histopathology 50 (2007) 203-209
165. Miyashita M., Makino H., Katsuta M., Nomura T., Shinji S., Kashiwabara M., Takahashi K., Kudo M., Ishiwata T., Naito Z., et al. Cyclo-oxygenase-2 over-expression is associated with human esophageal squamous cell carcinoma. J Nippon Med Sch 73 (2006) 308-313
166. Alici S., Ugras S., Bayram I., and Izmirli M. Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma. Adv Ther 23 (2006) 672-679
167. France M., Drew P.A., Dodd T., and Watson D.I. Cyclo-oxygenase-2 expression in esophageal adenocarcinoma as a determinant of clinical outcome following esophagectomy. Dis Esophagus 17 (2004) 136-140
168. Takatori H., Natsugoe S., Okumura H., Matsumoto M., Uchikado Y., Setoyama T., Sasaki K., Tamotsu K., Owaki T., Ishigami S., et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 34 (2008) 397-402
169. Yoshikawa R., Fujiwara Y., Koishi K., Kojima S., Matsumoto T., Yanagi H., Yamamura T., Hashimoto-Tamaoki T., Nishigami T., and Tsujimura T. Cyclooxygenase-2 expression after preoperative chemoradiotherapy correlates with more frequent esophageal cancer recurrence. World J Gastroenterol 13 (2007) 2283-2288
170. Cadden I., Johnston B.T., Turner G., McCance D., Ardill J., and McGinty A. An evaluation of cyclooxygenase-2 as a prognostic biomarker in mid-gut carcinoid tumours. Neuroendocrinology 86 (2007) 104-111
171. Karamitopoulou E., Tornillo L., Zlobec I., Cioccari L., Carafa V., Borner M., Schaffner T., Brunner T., Diamantis I., Zimmermann A., et al. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol 130 (2008) 780-786
172. Gao Y.W., Chen Y.X., Wang Z.M., Zhou L.D., Li X.Y., Li L.X., Luo Q.Z., Tian W., Fu C.Y., and Zhou J.H. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma. Hepatogastroenterology 55 (2008) 345-350
173. El-Bassiouny A.E., Zoheiry M.M., Nosseir M.M., El-Ahwany E.G., Ibrahim R.A., and El-Bassiouni N.E. Expression of cyclooxygenase-2 and transforming growth factor-beta1 in HCV-induced chronic liver disease and hepatocellular carcinoma. MedGenMed 9 (2007) 45
174. Iwamoto A., Ikeguchi M., Matsumoto S., Hukumoto Y., Inoue M., Ozaki T., Ataka M., Tanida T., Endo K., Katano K., et al. Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma. Tumorigenesis 92 (2006) 130-133
175. Tang T.C., Poon R.T., Lau C.P., Xie D., and Fan S.T. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J Gastroenterol 11 (2005) 1896-1902
176. Fumino S., Tokiwa K., Ono S., and Iwai N. Cyclooxygenase-2 expression in the gallbladder of patients with anomalous arrangement of the pancreaticobiliary duct. J Pediatr Surg 38 (2003) 585-589
177. Schlosser W., Schlosser S., Ramadani M., Gansauge F., Gansauge S., and Beger H.G. Cyclooxygenase-2 is overexpressed in chronic pancreatitis. Pancreas 25 (2002) 26-30
178. Niijima M., Yamaguchi T., Ishihara T., Hara T., Kato K., Kondo F., and Saisho H. Immunohistochemical analysis and in situ hybridization of cyclooxygenase-2 expression in intraductal papillary-mucinous tumors of the pancreas. Cancer 94 (2002) 1565-1573
179. Santini D., Vincenzi B., Tonini G., Scarpa S., Vasaturo F., Malacrino C., Vecchio F., Borzomati D., Valeri S., Coppola R., et al. Cyclooxygenase-2 overexpression is associated with a poor outcome in resected ampullary cancer patients. Clin Cancer Res 11 (2005) 3784-3789
180. Nakamoto R.H., Uetake H., Iida S., Kolev Y.V., Soumaoro L.T., Takagi Y., Yasuno M., and Sugihara K. Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. Jpn J Clin Oncol 37 (2007) 679-685
181. Ogino S., Kirkner G.J., Nosho K., Irahara N., Kure S., Shima K., Hazra A., Chan A.T., Dehari R., Giovannucci E.L., et al. Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14 (2008) 8221-8227. An important evidence for the role of COX-2 in colon cancer.
182. Soumaoro L.T., Uetake H., Higuchi T., Takagi Y., Enomoto M., and Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 10 (2004) 8465-8471
183. Abe A., Fukui H., Fujii S., Fujita M., Mukawa K., Ichikawa K., Tomita S., Ono Y., Imai Y., Imura J., et al. Involvement of cyclooxygenase-2 and vascular endothelial growth factor in vascularization and lymph node metastasis of colorectal cancers with submucosal invasion. J Gastroenterol Hepatol 22 (2007) 1071-1077
184. Cressey R., Pimpa S., Tontrong W., Watananupong O., and Leartprasertsuke N. Expression of cyclooxygenase-2 in colorectal adenocarcinoma is associated with p53 accumulation and hdm2 overexpression. Cancer Lett 233 (2006) 232-239
185. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
186. Konno H., Baba M., Shoji T., Ohta M., Suzuki S., and Nakamura S. Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer. Clin Exp Metastasis 19 (2002) 527-534
187. Masunaga R., Kohno H., Dhar D.K., Ohno S., Shibakita M., Kinugasa S., Yoshimura H., Tachibana M., Kubota H., and Nagasue N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6 (2000) 4064-4068
188. Yamagata R., Shimoyama T., Fukuda S., Yoshimura T., Tanaka M., and Munakata A. Cyclooxygenase-2 expression is increased in early intestinal-type gastric cancer and gastric mucosa with intestinal metaplasia. Eur J Gastroenterol Hepatol 14 (2002) 359-363
189. Joo Y.E., Oh W.T., Rew J.S., Park C.S., Choi S.K., and Kim S.J. Cyclooxygenase-2 expression is associated with well-differentiated and intestinal-type pathways in gastric carcinogenesis. Digestion 66 (2002) 222-229
190. Shi H., Xu J.M., Hu N.Z., and Xie H.J. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 9 (2003) 1421-1426
191. Tatsuguchi A., Matsui K., Shinji Y., Gudis K., Tsukui T., Kishida T., Fukuda Y., Sugisaki Y., Tokunaga A., Tajiri T., et al. Cyclooxygenase-2 expression correlates with angiogenesis and apoptosis in gastric cancer tissue. Hum Pathol 35 (2004) 488-495
192. Petersen S., Haroske G., Hellmich G., Ludwig K., Petersen C., and Eicheler W. COX-2 expression in rectal carcinoma: immunohistochemical pattern and clinical outcome. Anticancer Res 22 (2002) 1225-1230
193. Hammam O.A., Aziz A.A., Roshdy M.S., and Abdel Hadi A.M. Possible role of cyclooxygenase-2 in schistosomal and non-schistosomal-associated bladder cancer. Medscape J Med 10 (2008) 60
194. Shirahama T., Arima J., Akiba S., and Sakakura C. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer 92 (2001) 188-193
195. Kömhoff M., Guan Y., Shappell H.W., Davis L., Jack G., Shyr Y., Koch M.O., Shappell S.B., and Breyer M.D. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157 (2000) 29-35
196. Shariat S.F., Matsumoto K., Kim J., Ayala G.E., Zhou J.H., Jian W., Benedict W.F., and Lerner S.P. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol 170 (2003) 985-989
197. Khor L.Y., Bae K., Pollack A., Hammond M.E., Grignon D.J., Venkatesan V.M., Rosenthal S.A., Ritter M.A., Sandler H.M., Hanks G.E., et al. COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol 8 (2007) 912-920
198. Yoshimura R., Sano H., Masuda C., Kawamura M., Tsubouchi Y., Chargui J., Yoshimura N., Hla T., and Wada S. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89 (2000) 589-596
199. Guo G.L., Yang G.L., Li Z.Y., You J., Yang K., Huang D.P., Hu X.Q., and Zhang X.H. The effect of cyclooxygenase-2 on lymphangiogenesis in breast cancer. Zhonghua Wai Ke Za Zhi 46 (2008) 132-135
200. Costa C., Soares R., Reis-Filho J.S., Leitao D., Amendoeira I., and Schmitt F.C. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 55 (2002) 429-434
201. Haffty B.G., Yang Q., Moran M.S., Tan A.R., and Reiss M. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys 71 (2008) 1006-1013
202. Nassar A., Radhakrishnan A., Cabrero I.A., Cotsonis G., and Cohen C. COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 15 (2007) 255-259
203. Lu S., Yu G., Zhu Y., and Archer M.C. Cyclooxygenase-2 overexpression in MCF-10F human breast epithelial cells inhibits proliferation, apoptosis and differentiation, and causes partial transformation. Int J Cancer 116 (2005) 847-852
204. Leo C., Faber S., Hentschel B., Hockel M., and Horn L.C. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue. Ann Diagn Pathol 10 (2006) 327-332
205. Gaffney D.K., Haslam D., Tsodikov A., Hammond E., Seaman J., Holden J., Lee R.J., Zempolich K., and Dodson M. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 56 (2003) 922-928
206. Ferrandina G., Lauriola L., Zannoni G.F., Distefano M.G., Legge F., Salutari V., Gessi M., Maggiano N., Scambia G., and Ranelletti F.O. Expression of cyclooxygenase-2 (COX-2) in tumour and stroma compartments in cervical cancer: clinical implications. Br J Cancer 87 (2002) 1145-1152
207. Miyata Y., Koga S., Kanda S., Nishikido M., Hayashi T., and Kanetake H. Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9 (2003) 1741-1749
208. Fagotti A., Ferrandina G., Fanfani F., Legge F., Lauriola L., Gessi M., Castelli P., Barbieri F., Minelli L., and Scambia G. Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters. Hum Reprod 19 (2004) 393-397
209. Fujimoto J., Toyoki H., Sakaguchi H., Jahan I., Alam S.M., and Tamaya T. Clinical implications of expression of cyclooxygenase-2 related to angiogenesis in ovarian cancer. Oncol Rep 15 (2006) 21-25
210. Ali-Fehmi R., Che M., Khalifeh I., Malone J.M., Morris R., Lawrence W.D., and Munkarah A.R. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma. Cancer 98 (2003) 1423-1429
211. Denkert C., Köbel M., Pest S., Koch I., Berger S., Schwabe M., Siegert A., Reles A., Klosterhalfen B., and Hauptmann S. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 160 (2002) 893-903
212. Seo S.S., Song Y.S., Kang D.H., Park I.A., Bang Y.J., Kang S.B., and Lee H.P. Expression of cyclooxygenase-2 in association with clinicopathological prognostic factors and molecular markers in epithelial ovarian cancer. Gynecol Oncol 92 (2004) 927-935
213. Lou W.Z., Shen K., Zhang Y., and Lang J.H. Relationship of cyclooxygenase 2 expression and chemotherapy response and prognosis in human ovarian carcinoma. Zhonghua Fu Chan Ke Za Zhi 39 (2004) 529-532
214. Guo X., Chen Y., Xu Z., Xu Z., Qian Y., and Yu X. Prognostic significance of VEGF-C expression in correlation with COX-2, lymphatic microvessel density, and clinicopathologic characteristics in human non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 41 (2009) 217-222
215. Dong P., Li X., Yu Z., and Lu G. Expression of cyclooxygenase-2, vascular endothelial growth factor and matrix metalloproteinase-2 in patients with primary laryngeal carcinoma: a tissue microarray study. J Laryngol Otol 121 (2007) 1177-1183
216. Sackett M.K., Bairati I., Meyer F., Jobin E., Lussier S., Fortin A., Gélinas M., Nabid A., Brochet F., and Têtu B. Prognostic significance of cyclooxygenase-2 overexpression in glottic cancer. Clin Cancer Res 14 (2008) 67-73
217. Tjiu J.W., Liao Y.H., Lin S.J., Huang Y.L., Tsai W.L., Chu C.Y., Kuo M.L., and Jee S.H. Cyclooxygenase-2 overexpression in human basal cell carcinoma cell line increases antiapoptosis, angiogenesis, and tumorigenesis. J Invest Dermatol 126 (2006) 1143-1151
218. Shono T., Tofilon P.J., Bruner J.M., Owolabi O., and Lang F.F. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 61 (2001) 4375-4381
219. Crazzolara R., Kreczy A., Mann G., Heitger A., Eibl G., Fink F.M., Möhle R., and Meister B. High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol 115 (2001) 545-553
220. Arai J., Yasukawa M., Yakushijin Y., Miyazaki T., and Fujita S. Stromal cells in lymph nodes attract B-lymphoma cells via production of stromal cell-derived factor-1. Eur J Haematol 64 (2000) 323-332
221. Ottaiano A., Franco R., Aiello Talamanca A., Liguori G., Tatangelo F., Delrio P., Nasti G., Barletta E., Facchini G., Daniele B., et al. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 12 (2006) 2795-2803
222. Mochizuki H., Matsubara A., Teishima J., Mutaguchi K., Yasumoto H., Dahiya R., Usui T., and Kamiya K. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: a possible predictor of metastasis. Biochem Biophys Res Commun 320 (2004) 656-663
223. Holm N.T., Byrnes K., Li B.D., Turnage R.H., Abreo F., Mathis J.M., and Chu Q.D. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 141 (2007) 53-59. An importance of CXCR4 for breast cancer recurrence.
224. Salvucci O., Bouchard A., Baccarelli A., Deschênes J., Sauter G., Simon R., Bianchi R., and Basik M. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat 97 (2006) 275-283
225. Cabioglu N., Sahin A.A., Morandi P., Meric-Bernstam F., Islam R., Lin H.Y., Bucana C.D., Gonzalez-Angulo A.M., Hortobagyi G.N., and Cristofanilli M. Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol 20 (2009) 1013-1019
226. Kang H., Watkins G., Douglas-Jones A., Mansel R.E., and Jiang W.G. The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 14 (2005) 360-367
227. Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., Zhou X., Xia W., Hortobagyi G.N., Yu D., et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6 (2004) 459-469
228. Guo Z., Cai S., Fang R., Chen H., Du J., Tan Y., Ma W., Hu H., Cai S., and Liu Y. The synergistic effects of CXCR4 and EGFR on promoting EGF-mediated metastasis in ovarian cancer cells. Colloids Surf B Biointerfaces 60 (2007) 1-6
229. Kodama J., Hasengaowa, Kusumoto T., Seki N., Matsuo T., Ojima Y., Nakamura K., Hongo A., and Hiramatsu Y. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol 18 (2007) 70-76
230. de Bont E.S., Rosati S., Jacobs S., Kamps W.A., and Vellenga E. Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol 113 (2001) 296-304
231. Kuramoto K., Sakai A., Shigemasa K., Takimoto Y., Asaoku H., Tsujimoto T., Oda K., Kimura A., Uesaka T., Watanabe H., et al. High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Haematol 116 (2002) 158-161
232. Han U., Can O.I., Han S., Kayhan B., and Onal B.U. Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma?. Dis Esophagus 20 (2007) 379-385
233. Kimura S., Kitadai Y., Tanaka S., Kuwai T., Hihara J., Yoshida K., Toge T., and Chayama K. Expression of hypoxia-inducible factor (HIF)-1alpha is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer 40 (2004) 1904-1912
234. Shih C.H., Ozawa S., Ando N., Ueda M., and Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 6 (2000) 1161-1168
235. Dassoulas K., Gazouli M., Rizos S., Theodoropoulos G., Christoni Z., Nikiteas N., and Karakitsos P. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 48 (2009) 563-569
236. Romano M., Cuomo A., Tuccillo C., Salerno R., Rocco A., Staibano S., Mascolo M., Sciaudone G., Mucherino C., Giuliani A., et al. Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis. Dis Colon Rectum 50 (2007) 650-659
237. Al-Harris E.S., Al-Janabi A.A., Al-Toriahi K.M., and Yasseen A.A. Over expression of vascular endothelial growth factor in correlation to Ki-67, grade, and stage of breast cancer. Saudi Med J 29 (2008) 1099-1104
238. Yilmaz A., Ernam D., Unsal E., Demirag F., Atikcan S., and Tastepe I. Vascular endothelial growth factor immunostaining correlates with postoperative relapse and survival in non-small cell lung cancer. Arch Med Res 38 (2007) 764-768
239. Vanasse G.J., Winn R.K., Rodov S., Zieske A.W., Li J.T., Tupper J.C., Tang J., Raines E.W., Peters M.A., Yeung K.Y., et al. Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and de novo follicular lymphoma. Mol Cancer Res 2 (2004) 620-631
240. Ma X.T., Wang S., Ye Y.J., Du R.Y., Cui Z.R., and Somsouk M. Constitutive activation of Stat3 signaling pathway in human colorectal carcinoma. World J Gastroenterol 10 (2004) 1569-1573
241. Zhang H., Wang S., Zhang Y.C., Ye Y.J., Cui Z.R., and Fang W.G. Correlation between Stat3 signal transduction pathway and expression of cyclooxygenase-2 in colorectal cancer cells. Zhonghua Yi Xue Za Zhi 85 (2005) 2899-2904
242. Hbibi A.T., Lagorce C., Wind P., Spano J.P., Des Guetz G., Milano G., Benamouzig R., Rixe O., Morere J.F., Breau J.L., et al. Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value. Cancer Biomark 4 (2008) 83-91
243. Dhir R., Ni Z., Lou W., DeMiguel F., Grandis J.R., and Gao A.C. Stat3 activation in prostatic carcinomas. Prostate 51 (2002) 241-246
244. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., Bowman T., Falcone R., Fairclough R., Cantor A., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 62 (2002) 6659-6666
245. Torres-Roca J.F., DeSilvio M., Mora L.B., Khor L.Y., Hammond E., Ahmad N., Jove R., Forman J., Lee R.J., Sandler H., et al. Activated STAT3 as a correlate of distant metastasis in prostate cancer: a secondary analysis of Radiation Therapy Oncology Group 86-10. Urology 69 (2007) 505-509
246. Emilie D., Devergne O., Raphael M., Coumbaras L.J., and Galanaud P. Production of interleukin-6 in high grade B lymphomas. Curr Top Microbiol Immunol 182 (1992) 349-355
247. Seymour J.F., Talpaz M., Cabanillas F., Wetzler M., and Kurzrock R. Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13 (1995) 575-582
248. Preti H.A., Cabanillas F., Talpaz M., Tucker S.L., Seymour J.F., and Kurzrock R. Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127 (1997) 186-194
249. Shimamoto T., Hayashi S., Ando K., Yguchi M., Miyazawa K., Kimura Y., Mukai K., Serizawa H., and Ohyashiki K. Anaplastic large-cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL-6 serum levels after long-term immunosuppressive therapy. Am J Hematol 66 (2001) 49-52
250. Kato H., Kinoshita T., Suzuki S., Nagasaka T., Murate T., Saito H., and Hotta T. Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with B-cell non-Hodgkin's lymphoma: correlation with extent of IL-6 expression and serum concentration. Br J Haematol 92 (1996) 1014-1021
251. Voorzanger N., Touitou R., Garcia E., Delecluse H.J., Rousset F., Joab I., Favrot M.C., and Blay J.Y. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56 (1996) 5499-5505
252. Kossakowska A.E., Edwards D.R., Prusinkiewicz C., Zhang M.C., Guo D., Urbanski S.J., Grogan T., Marquez L.A., and Janowska-Wieczorek A. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood 94 (1999) 2080-2089
253. Seymour J.F., Talpaz M., Hagemeister F.B., Cabanillas F., and Kurzrock R. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease. Am J Med 102 (1997) 21-28
254. Ludwig H., Nachbaur D.M., Fritz E., Krainer M., and Huber H. Interleukin-6 is a prognostic factor in multiple myeloma. Blood 77 (1991) 2794-2795
255. Reibnegger G., Krainer M., Herold M., Ludwig H., Wachter H., and Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 51 (1991) 6250-6253
256. Dvorakova K., Payne C.M., Ramsey L., Holubec H., Sampliner R., Dominguez J., Dvorak B., Bernstein H., Bernstein C., Prasad A., et al. Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin Cancer Res 10 (2004) 2020-2028
257. Komoda H., Tanaka Y., Honda M., Matsuo Y., Hazama K., and Takao T. Interleukin-6 levels in colorectal cancer tissues. World J Surg 22 (1998) 895-898
258. Kinoshita T., Ito H., and Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 85 (1999) 2526-2531
259. Ito H., and Miki C. Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients. Scand J Gastroenterol 34 (1999) 1139-1143
260. Garza-González E., Bosques-Padilla F.J., El-Omar E., Hold G., Tijerina-Menchaca R., Maldonado-Garza H.J., and Pérez-Pérez G.I. Role of the polymorphic IL-1B, IL-1RN and TNF-A genes in distal gastric cancer in Mexico. Int J Cancer 114 (2005) 237-241
261. Ashizawa T., Okada R., Suzuki Y., Takagi M., Yamazaki T., Sumi T., Aoki T., Ohnuma S., and Aoki T. Clinical significance of interleukin-6 (IL-6) in the spread of gastric cancer: role of IL-6 as a prognostic factor. Gastric Cancer 8 (2005) 124-131
262. Chung Y.C., Chaen Y.L., and Hsu C.P. Clinical significance of tissue expression of interleukin-6 in colorectal carcinoma. Anticancer Res 26 (2006) 3905-3911
263. El-Salahy E.M. Evaluation of cytokeratin-19 & cytokeratin-20 and interleukin-6 in Egyptian bladder cancer patients. Clin Biochem 35 (2002) 607-613
264. Zhang G.J., and Adachi I. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19 (1999) 1427-1432
265. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Cheng W.F., Chang M.C., Su J.L., and Hsieh C.Y. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of Mcl-1 through a PI 3-K/Akt pathway. Oncogene 20 (2001) 5799-5809
266. Wang L., Tang Z., and Sun H. Nitric oxide synthase and vascular endothelial growth factor expression in hepatocellular carcinoma and their relation to angiogenesis. Zhonghua Zhong Liu Za Zhi 22 (2000) 301-303
267. Klotz T., Bloch W., Jacobs G., Niggemann S., Engelmann U., and Addicks K. Immunolocalization of inducible and constitutive nitric oxide synthases in human bladder cancer. Urology 54 (1999) 416-419
268. Fujimoto H., Ando Y., Yamashita T., Terazaki H., Tanaka Y., Sasaki J., Matsumoto M., Suga M., and Ando M. Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res 88 (1997) 1190-1198
269. Natarajan R., Esworthy R., Bai W., Gu J.L., Wilczynski S., and Nadler J. Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. J Clin Endocrinol Metab 82 (1997) 1790-1798
270. Wilborn J., Bailie M., Coffey M., Burdick M., Strieter R., and Peters-Golden M. Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 97 (1996) 1827-1836